The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A03 | Drugs for functional gastrointestinal disorders | |
| 3 | A03A | DRUGS FOR FUNCTIONAL BOWEL DISORDERS | |
| 4 | A03AA | Synthetic anticholinergics, esters with tertiary amino group | |
| 5 | A03AA05 | Trimebutine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.6 g |
| Active Ingredient | Description | |
|---|---|---|
| Trimebutine |
Trimebutine maleate is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has a marked antiserotonin activity especially on ‘M’ receptors. It induces regulation of spontaneous activity and increases synchronization between electrophysiological spikes and contractions in isolated guinea pig taenia coli and ileum. However, it does not alter normal motility, but regulates abnormal intestinal activity. |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
